Brintellix

Country: European Union

Language: English

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

Vortioxetine

Available from:

H. Lundbeck A/S

ATC code:

N06AX26

INN (International Name):

vortioxetine

Therapeutic group:

Psychoanaleptics,

Therapeutic area:

Depressive Disorder, Major

Therapeutic indications:

Treatment of major depressive episodes in adults.

Product summary:

Revision: 23

Authorization status:

Authorised

Authorization date:

2013-12-18

Patient Information leaflet

                                72
B. PACKAGE LEAFLET
v.
77.0
REG_00028683
73
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
BRINTELLIX 5 MG FILM-COATED TABLETS
vortioxetine
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Brintellix is and what it is used for
2.
What you need to know before you take Brintellix
3.
How to take Brintellix
4.
Possible side effects
5.
How to store Brintellix
6.
Contents of the pack and other information
1.
WHAT BRINTELLIX IS AND WHAT IT IS USED FOR
Brintellix contains the active substance vortioxetine. It belongs to a
group of medicines called
antidepressants.
Brintellix is used to treat major depressive episodes in adults.
Brintellix has been shown to reduce the broad range of depressive
symptoms, including sadness, inner
tension (feeling anxious), sleep disturbances (reduced sleep), reduced
appetite, difficulty in
concentrating, feelings of worthlessness, loss of interest in
favourite activities, feeling of being slowed
down.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE BRINTELLIX
DO NOT TAKE BRINTELLIX:
-
if you are allergic to vortioxetine or any of the other ingredients of
this medicine (listed in
section 6).
-
if you are taking other medicines for depression known as
non-selective monoamine oxidase
inhibitors or selective MAO-A inhibitors. Ask your doctor if you are
uncertain.
WARNINGS AND PRECAUTIONS
Talk to your doctor or pharmacist before taking Brintellix if you:
-
are taking medicines with a so-called serotonergic effect, such as:
-
tramadol and similar medicines (strong painkillers).
-
sumatr
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
v.
77.0
REG_00028683
2
1.
NAME OF THE MEDICINAL PRODUCT
Brintellix 5 mg film-coated tablets
Brintellix 10 mg film-coated tablets
Brintellix 15 mg film-coated tablets
Brintellix 20 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Brintellix 5 mg film-coated tablets
Each film-coated tablet contains vortioxetine hydrobromide equivalent
to 5 mg vortioxetine.
Brintellix 10 mg film-coated tablets
Each film-coated tablet contains vortioxetine hydrobromide equivalent
to 10 mg vortioxetine.
Brintellix 15 mg film-coated tablets
Each film-coated tablet contains vortioxetine hydrobromide equivalent
to 15 mg vortioxetine.
Brintellix 20 mg film-coated tablets
Each film-coated tablet contains vortioxetine hydrobromide equivalent
to 20 mg vortioxetine.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet (tablet)
Brintellix 5 mg film-coated tablets
Pink, almond-shaped (5 x 8.4 mm) film-coated tablet engraved with
“TL” on one side and “5” on the
other side.
Brintellix 10 mg film-coated tablets
Yellow, almond-shaped (5 x 8.4 mm) film-coated tablet engraved with
“TL” on one side and “10” on
the other side.
Brintellix 15 mg film-coated tablets
Orange, almond-shaped (5 x 8.4 mm) film-coated tablet engraved with
“TL” on one side and “15” on
the other side.
Brintellix 20 mg film-coated tablets
Red, almond-shaped (5 x 8.4 mm) film-coated tablet engraved with
“TL” on one side and “20” on the
other side.
v.
77.0
REG_00028683
3
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Brintellix is indicated for the treatment of major depressive episodes
in adults.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
The starting and recommended dose of Brintellix is 10 mg vortioxetine
once daily in adults less than
65 years of age.
Depending on individual patient response, the dose may be increased to
a maximum of 20 mg
vortioxetine once daily or decreased to a minimum of 5 mg vortioxetine
once daily.
After the dep
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 16-01-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 16-01-2024
Public Assessment Report Public Assessment Report Bulgarian 14-01-2014
Patient Information leaflet Patient Information leaflet Spanish 16-01-2024
Public Assessment Report Public Assessment Report Spanish 14-01-2014
Patient Information leaflet Patient Information leaflet Czech 16-01-2024
Public Assessment Report Public Assessment Report Czech 14-01-2014
Patient Information leaflet Patient Information leaflet Danish 16-01-2024
Public Assessment Report Public Assessment Report Danish 14-01-2014
Patient Information leaflet Patient Information leaflet German 16-01-2024
Public Assessment Report Public Assessment Report German 14-01-2014
Patient Information leaflet Patient Information leaflet Estonian 16-01-2024
Public Assessment Report Public Assessment Report Estonian 14-01-2014
Patient Information leaflet Patient Information leaflet Greek 16-01-2024
Public Assessment Report Public Assessment Report Greek 14-01-2014
Patient Information leaflet Patient Information leaflet French 16-01-2024
Public Assessment Report Public Assessment Report French 14-01-2014
Patient Information leaflet Patient Information leaflet Italian 16-01-2024
Public Assessment Report Public Assessment Report Italian 14-01-2014
Patient Information leaflet Patient Information leaflet Latvian 16-01-2024
Public Assessment Report Public Assessment Report Latvian 14-01-2014
Patient Information leaflet Patient Information leaflet Lithuanian 16-01-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 16-01-2024
Public Assessment Report Public Assessment Report Lithuanian 14-01-2014
Patient Information leaflet Patient Information leaflet Hungarian 16-01-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 16-01-2024
Public Assessment Report Public Assessment Report Hungarian 14-01-2014
Patient Information leaflet Patient Information leaflet Maltese 16-01-2024
Public Assessment Report Public Assessment Report Maltese 14-01-2014
Patient Information leaflet Patient Information leaflet Dutch 16-01-2024
Public Assessment Report Public Assessment Report Dutch 14-01-2014
Patient Information leaflet Patient Information leaflet Polish 16-01-2024
Public Assessment Report Public Assessment Report Polish 14-01-2014
Patient Information leaflet Patient Information leaflet Portuguese 16-01-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 16-01-2024
Public Assessment Report Public Assessment Report Portuguese 14-01-2014
Patient Information leaflet Patient Information leaflet Romanian 16-01-2024
Public Assessment Report Public Assessment Report Romanian 14-01-2014
Patient Information leaflet Patient Information leaflet Slovak 16-01-2024
Public Assessment Report Public Assessment Report Slovak 14-01-2014
Patient Information leaflet Patient Information leaflet Slovenian 16-01-2024
Summary of Product characteristics Summary of Product characteristics Slovenian 16-01-2024
Public Assessment Report Public Assessment Report Slovenian 14-01-2014
Patient Information leaflet Patient Information leaflet Finnish 16-01-2024
Public Assessment Report Public Assessment Report Finnish 14-01-2014
Patient Information leaflet Patient Information leaflet Swedish 16-01-2024
Public Assessment Report Public Assessment Report Swedish 14-01-2014
Patient Information leaflet Patient Information leaflet Norwegian 16-01-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 16-01-2024
Patient Information leaflet Patient Information leaflet Icelandic 16-01-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 16-01-2024
Patient Information leaflet Patient Information leaflet Croatian 16-01-2024
Public Assessment Report Public Assessment Report Croatian 14-01-2014

Search alerts related to this product

View documents history